Can You Take Zepbound (Tirzepatide) While Pregnant?

The fast answer

No. Zepbound is not for use in pregnancy. Its FDA label says plainly that weight loss offers no benefit to a pregnant patient and may cause fetal harm, and instructs you to discontinue Zepbound when a pregnancy is recognized¹.

The question people actually get wrong is the other timing question — how far ahead of trying to conceive you are supposed to stop. There is a widely repeated "two months" rule. It is real, it is on a label, and it is not on Zepbound's.

A few links here go to programs we may earn a referral fee from. It never moves anyone up a list. See our disclosure.

The two-month rule belongs to semaglutide

Read the left column twice, because the asymmetry is the whole point. Semaglutide's label carries an explicit, numbered pre-pregnancy instruction: "discontinue WEGOVY in patients at least 2 months before they plan to become pregnant to account for the long half-life of semaglutide"². Ozempic's label says the same thing in almost the same words³.

Tirzepatide's label has no equivalent sentence. Section 8.3 of the Zepbound label — the section where that instruction would live — contains only the contraception paragraph¹. That is not an oversight you should read as "so it must be fine to conceive on it." It means the manufacturer has not put a number on it, so the number has to come from your clinician, not from a semaglutide article you read first.

Why "about a week per dose" is the wrong figure

You will see the washout described as roughly a week per dose. That is semaglutide's half-life, and a half-life is not a washout. Wegovy's own pharmacology section says semaglutide will be present in the circulation for about 5 to 7 weeks after the last injection² — which is precisely why the instruction is two months and not one week. Planning a conception attempt off the half-life understates the wait by roughly eight-fold.

Tirzepatide's half-life is shorter, about 5 days¹. That is a genuine pharmacological difference between the drugs, and it is the likeliest reason its label never needed a two-month clause. It is still not a licence to time a pregnancy yourself.

If you are already pregnant

Stop the injection and call your prescriber the same day — not at your next scheduled visit. Then take a breath, because the outcome data are more reassuring than the label's tone suggests.

• A 2026 systematic review and meta-analysis pooled six studies covering 286,599 women — 43,577 exposed to a GLP-1 around conception and 243,022 unexposed. Major congenital malformations were no more common in the exposed group (relative risk 1.02, 95% CI 0.96–1.08), and preterm birth, stillbirth, and small- and large-for-gestational-age babies were not significantly elevated either. The authors are explicit that this is not proof of safety, only an absence of signal⁴.
• A Danish nationwide cohort of 756,636 singleton pregnancies, 529 of them with periconceptional GLP-1 exposure, found a raised preterm-birth risk only in women taking the drug for diabetes (semaglutide adjusted OR 1.84, 95% CI 1.24–2.71). For women taking it for weight management, there was no association (semaglutide adjusted OR 0.71, 95% CI 0.30–1.70) — pointing at the diabetes rather than the drug⁵.

Both Zepbound and Wegovy also run pregnancy exposure registries, and your clinician can enrol you¹². It costs you a phone call and it is how the next mother gets better numbers than you did.

The contraception line that is Zepbound's alone

This one runs the other way — the instruction exists for tirzepatide and not for semaglutide. Zepbound can reduce the effectiveness of oral hormonal contraceptives by slowing gastric emptying, so the label tells you to switch to a non-oral method or add a barrier method for 4 weeks after starting and 4 weeks after each dose escalation¹. IUDs, implants, the shot, the patch and the ring are not swallowed and are unaffected.

Semaglutide's labels carry no contraceptive instruction at all. Ozempic's label reports a dedicated interaction study with an ethinylestradiol/levonorgestrel pill and found no clinically relevant interaction³. If you want the full backup-method plan, it is in GLP-1s and birth control.

What to put in front of your clinician

1. 1.Which drug you are on, by molecule — tirzepatide and semaglutide are not interchangeable in this conversation.
2. 2.When you want to start trying, in months. That is what sets the stop date.
3. 3.Your current contraception, and whether it is swallowed.
4. 4.Whether you take it for diabetes or for weight, because the Danish data separate on exactly that line⁵.

If you are stopping in order to conceive rather than because of a side effect, the taper and the weight-regain question are a separate planning problem — that is maintenance and the off-ramp. And if you are already postpartum and wondering about restarting, the feeding question has its own answer in Wegovy and breastfeeding.